% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • faosto faosto Oct 13, 2012 7:34 PM Flag

    So what are the chances the FDA panel approves this?

    My assessment based on what I've read is that AEGR should get a bout $300,000,000 in rtevenues for this within five years. ISIS will also get another 300 mm. There are approx 6,000 people with this rarte disease in the US and Europe, with about half in the US. Assuming that 2000 are on this @ $300K per year, that's 600mm split between two companies. I thiknk that's conservative. At 20% profit, AEGR has the potential to achieve $2-3 eps in five years. That makes this a $40-50 buyout candidate, and with 10% short, this will easily sail to $30 or at least high $20's. I think there is greater than 80% chance of approval. the side affects are gastro-intestinal, but can be managed with low fat diet. That is an easy trade off for patients that must have their blood filtered multiple times a month to remove all of the yellow cholesterol from it. The next obvious trial will be a combination of AEGR's and ISIS' drug.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.44-0.03(-2.04%)Jul 29 4:00 PMEDT